CDK7 and cancer: The prospect of using CDK7 inhibitors to overcome resistance to prior treatments in cancer is exciting, and it is crucial that information garnered from preclinical studies of CDK7 inhibitors in the context of acquired drug-resistance continues to be considered during clinical trial design.